Tags

Type your tag names separated by a space and hit enter

Analysis of the risk of solid tumor following Hodgkin's disease.
Haematologica. 1997 Jan-Feb; 82(1):57-63.H

Abstract

BACKGROUND AND OBJECTIVE

This study examines the occurrence of solid tumor (ST) in relation to the different types of therapy (radiotherapy, chemotherapy and radiochemotherapy; splenectomy or splenic irradiation vs no splenectomy-no splenic irradiation) received by patients treated for Hodgkin's disease (HD).

METHODS

The study included 1,045 HD patients treated at the Department of Radiation Oncology, the Institute of Radiology and the Department of Human Biopathology, Hematology Section, University of Rome, "La Sapienza", from 1972 to 1992. For 23% of the patients the follow-up period was longer than 10 years. The average follow-up period was 72 months. For a more accurate calculation of the risk of ST occurrence, the patients were first divided into 3 subgroups according to initial treatment and then according to the total treatment they had received. Moreover, to establish a probable connection between solid tumor and splenic treatment the patients were also divided into 3 subgroups (splenectomy, splenic irradiation and no splenectomy/no splenic irradiation).

RESULTS

We recorded twenty-four cases of ST after initial treatment. Secondary solid tumor showed a cumulative risk of 0.2% and 13.4% at 5 and 20 years, respectively. After initial treatment with radiotherapy (RT) alone, the cumulative risk was 1.7% and 5.2% at 10 and 20 years, respectively; in the chemotherapy (CT) group, it was 2.4% and 18.1%; in the CT(+)RT group, it was 1.7% and 9%. No statistically significant differences were observed among the different types of treatment (splenectomy, splenic irradiation or no splenectomy/no splenic irradiation) as regards the occurrence of ST. According to multivariate analysis, the most important factor in the risk of ST was age (> 40). Relative risk was 5.2, p = 0.0001.

INTERPRETATION AND CONCLUSIONS

We conclude that an age of over 40 at diagnosis and treatment with CT alone greatly increase the risk of solid tumor occurrence.

Authors+Show Affiliations

Chair of Radiation Oncology, Hospital S. Maria di Collemaggio, University of L'Aquila, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

9107084

Citation

Maurizi Enrici, R, et al. "Analysis of the Risk of Solid Tumor Following Hodgkin's Disease." Haematologica, vol. 82, no. 1, 1997, pp. 57-63.
Maurizi Enrici R, Anselmo AP, Osti MF, et al. Analysis of the risk of solid tumor following Hodgkin's disease. Haematologica. 1997;82(1):57-63.
Maurizi Enrici, R., Anselmo, A. P., Osti, M. F., Santoro, M., Tombolini, V., Mandelli, F., & Biagini, C. (1997). Analysis of the risk of solid tumor following Hodgkin's disease. Haematologica, 82(1), 57-63.
Maurizi Enrici R, et al. Analysis of the Risk of Solid Tumor Following Hodgkin's Disease. Haematologica. 1997 Jan-Feb;82(1):57-63. PubMed PMID: 9107084.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Analysis of the risk of solid tumor following Hodgkin's disease. AU - Maurizi Enrici,R, AU - Anselmo,A P, AU - Osti,M F, AU - Santoro,M, AU - Tombolini,V, AU - Mandelli,F, AU - Biagini,C, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 57 EP - 63 JF - Haematologica JO - Haematologica VL - 82 IS - 1 N2 - BACKGROUND AND OBJECTIVE: This study examines the occurrence of solid tumor (ST) in relation to the different types of therapy (radiotherapy, chemotherapy and radiochemotherapy; splenectomy or splenic irradiation vs no splenectomy-no splenic irradiation) received by patients treated for Hodgkin's disease (HD). METHODS: The study included 1,045 HD patients treated at the Department of Radiation Oncology, the Institute of Radiology and the Department of Human Biopathology, Hematology Section, University of Rome, "La Sapienza", from 1972 to 1992. For 23% of the patients the follow-up period was longer than 10 years. The average follow-up period was 72 months. For a more accurate calculation of the risk of ST occurrence, the patients were first divided into 3 subgroups according to initial treatment and then according to the total treatment they had received. Moreover, to establish a probable connection between solid tumor and splenic treatment the patients were also divided into 3 subgroups (splenectomy, splenic irradiation and no splenectomy/no splenic irradiation). RESULTS: We recorded twenty-four cases of ST after initial treatment. Secondary solid tumor showed a cumulative risk of 0.2% and 13.4% at 5 and 20 years, respectively. After initial treatment with radiotherapy (RT) alone, the cumulative risk was 1.7% and 5.2% at 10 and 20 years, respectively; in the chemotherapy (CT) group, it was 2.4% and 18.1%; in the CT(+)RT group, it was 1.7% and 9%. No statistically significant differences were observed among the different types of treatment (splenectomy, splenic irradiation or no splenectomy/no splenic irradiation) as regards the occurrence of ST. According to multivariate analysis, the most important factor in the risk of ST was age (> 40). Relative risk was 5.2, p = 0.0001. INTERPRETATION AND CONCLUSIONS: We conclude that an age of over 40 at diagnosis and treatment with CT alone greatly increase the risk of solid tumor occurrence. SN - 0390-6078 UR - https://www.unboundmedicine.com/medline/citation/9107084/Analysis_of_the_risk_of_solid_tumor_following_Hodgkin's_disease_ L2 - http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=9107084 DB - PRIME DP - Unbound Medicine ER -